Sun Pharma reported FY26 profit growth: what it means for Sun Pharma stock

Published on 10/08/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue rose 12.00 percent to INR 582.20 billion. For Sun Pharma stock, net profit rose 5.00 percent to INR 114.79 billion.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma reported fiscal 2026 revenue of INR 582.20 billion, up 12.00 percent from the previous fiscal year, while net profit rose 5.00 percent to INR 114.79 billion, according to ScanX on September 22, 2026. The figures show a wider gap between Sun Pharma's top-line expansion and bottom-line growth.

Profit growth lagged revenue

Sun Pharma's fiscal 2026 EBITDA increased 16.10 percent to INR 177.31 billion, while EBITDA margin reached 30.30 percent, up from 29.00 percent in fiscal 2025, ScanX reported. That combination points to stronger operating performance, but the smaller net-profit increase means exceptional items and other below-operating-line effects remain important for investors assessing earnings quality.

The revenue mix also matters. India formulations contributed 33.00 percent of fiscal 2026 sales, while US formulations accounted for 29.00 percent, according to ScanX. The split gives Sun Pharma a diversified base, although the slower profit progression raises the importance of margin discipline as specialty medicines and international operations expand.

Cash gives strategy room

Sun Pharma ended fiscal 2026 with net cash of INR 301.40 billion, compared with INR 267.90 billion a year earlier, while operating cash flow reached INR 124.20 billion and free cash flow stood at INR 88.10 billion, ScanX reported. The balance-sheet comparison is a concrete counterweight to the profit-growth gap because it leaves the company with financial capacity for research, product launches and strategic investments.

Stock trades below the prior close

On the NSE, Sun Pharma was at INR 1,750.50 on October 8, 2026, at 1:32 p.m. IST, down 1.71 percent from the prior close of INR 1,781.00. The session range was INR 1,747.00 to INR 1,796.00, putting the latest quote near the lower end of that day's range and giving the earnings-quality question a direct market reference.